![Ocean Genomics Poster - ASCO 2023 with Yale Cancer Center - Identifying Molecular Predictors and Immunomodulatory Role of Dual Checkpoint Inhibitors in Small Cell Lung Cancer - Ocean Genomics Ocean Genomics Poster - ASCO 2023 with Yale Cancer Center - Identifying Molecular Predictors and Immunomodulatory Role of Dual Checkpoint Inhibitors in Small Cell Lung Cancer - Ocean Genomics](https://www.oceangenomics.com/wp-content/uploads/2023/06/2023-Abstract-scaled.jpg)
Ocean Genomics Poster - ASCO 2023 with Yale Cancer Center - Identifying Molecular Predictors and Immunomodulatory Role of Dual Checkpoint Inhibitors in Small Cell Lung Cancer - Ocean Genomics
![ASCO 2013 - Poster: Open-label, multicenter study of sipuleucel-T in men with metastatic castrate resistant prostate cancer (mCRPC) previously treated with sipuleucel-T: Evaluation of antigen presenting cell (APC) activation and ELISPOT data ASCO 2013 - Poster: Open-label, multicenter study of sipuleucel-T in men with metastatic castrate resistant prostate cancer (mCRPC) previously treated with sipuleucel-T: Evaluation of antigen presenting cell (APC) activation and ELISPOT data](https://www.urotoday.com/images/stories/conferences/asco/asco_2013_beers_Open-label_multicenter_study_of_sipuleucel-T.jpg)
ASCO 2013 - Poster: Open-label, multicenter study of sipuleucel-T in men with metastatic castrate resistant prostate cancer (mCRPC) previously treated with sipuleucel-T: Evaluation of antigen presenting cell (APC) activation and ELISPOT data
![ASCO 2013 - Poster: Impact of prior docetaxel (D) on sipuleucel-T (sip-T) product parameters in PROCEED patients ASCO 2013 - Poster: Impact of prior docetaxel (D) on sipuleucel-T (sip-T) product parameters in PROCEED patients](https://www.urotoday.com/images/asco_2013_proceed_higano_poster.jpg)
ASCO 2013 - Poster: Impact of prior docetaxel (D) on sipuleucel-T (sip-T) product parameters in PROCEED patients
![ASCO 2013 - Poster: A phase I study of the safety and pharmacokinetics of DSTP3086S, an anti-STEAP1 antibody-drug conjugate, in patients with metastatic castration-resistant prostate cancer ASCO 2013 - Poster: A phase I study of the safety and pharmacokinetics of DSTP3086S, an anti-STEAP1 antibody-drug conjugate, in patients with metastatic castration-resistant prostate cancer](https://www.urotoday.com/images/stories/conferences/asco/asco_2013_danila_STEAP_poster.jpg)
ASCO 2013 - Poster: A phase I study of the safety and pharmacokinetics of DSTP3086S, an anti-STEAP1 antibody-drug conjugate, in patients with metastatic castration-resistant prostate cancer
![ASCO 2013 - Poster: A randomized, phase II trial of sipuleucel-T with concurrent or sequential abiraterone acetate plus prednisone in metastatic castrate-resistant prostate cancer (mCRPC) ASCO 2013 - Poster: A randomized, phase II trial of sipuleucel-T with concurrent or sequential abiraterone acetate plus prednisone in metastatic castrate-resistant prostate cancer (mCRPC)](https://www.urotoday.com/images/stories/conferences/asco/asco_2013_abiraterone_small_poster.jpg)